# Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia

> **NCT02844361** · PHASE4 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 70 (actual)

## Conditions studied

- Waldenström Macroglobulinemia

## Interventions

- **PROCEDURE:** autologous stem cell transplantation
- **DRUG:** conventional chemotherapy

## Key facts

- **NCT ID:** NCT02844361
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2019-11
- **Final completion:** 2020-05
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844361, "Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02844361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*